The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review

Table 3

The comparison between groups.

Outcome	Treatment comparison			value
	A	B	95% CI
Polyp regression rate	Conbercept	Aflibercept	0.467 to 0.613	0.032
	Conbercept	Ranibizumab	0.372 to 0.501	<0.0001
	Aflibercept	Ranibizumab	0.367 to 0.489	0.002
BCVA	Conbercept	Aflibercept	0.352 to 0.797	0.171
	Conbercept	Ranibizumab	0.166 to 0.406	0.811
	Aflibercept	Ranibizumab	0.327 to 0.693	0.056
CRT	Conbercept	Aflibercept	1.063 to 1.610	0.331
	Conbercept	Ranibizumab	0.722 to 1.114	0.144
	Aflibercept	Ranibizumab	0.976 to 1.473	0.032
Injection frequency	Conbercept	Aflibercept	5.790 to 6.752	0.01
	Conbercept	Ranibizumab	4.263 to 6.772	0.501
	Aflibercept	Ranibizumab	5.719 to 6.523	<0.0001
Adverse events	Conbercept	Aflibercept	0.016 to 0.068	0.987
	Conbercept	Ranibizumab	0.020 to 0.072	0.879
	Aflibercept	Ranibizumab	0.027 to 0.061	0.912